Silk Road Medical Inc is a medical device company focused on improving the treatment of neurovascular diseases, particularly through minimally invasive procedures
The company's flagship product is designed to enhance the treatment of carotid artery disease, which can lead to stroke. By developing innovative technologies that facilitate less invasive options for patients and healthcare providers, Silk Road Medical aims to enhance clinical outcomes and improve the overall patient experience in neurovascular care. Their commitment to advancing medical technology positions them as a key player in the healthcare industry, striving to address critical needs in vascular health.
The top 10 positions in QQQ constitute almost half of its total weight. Although current tech leaders may have become too pricey two Invesco Nasdaq ETFs target future tech leaders: QQQJ and QQQS. Both have
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR system, a breakthrough in stroke prevention. Transaction closes in H2 2024.
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Stifel's upgraded outlook on Silk Road Medical as CEO Chas McKhann addresses concerns, unveils a compelling vision, and outlines strategic initiatives. Analysts upgrade to Buy with $20 price target, citing confidence in TCAR technology and long-term growth under McKhann's leadership.
Shares of TransCode Therapeutics, Inc. (NASDAQRNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
